Daan J. de Jong

Mr. Daan J. de Jong

UMC Utrecht
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2021 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
DJDaan J. de Jong
Daan J. de Jong
WVWouter Veldhuis
Wouter Veldhuis
FWFrank J. Wessels
Frank J. Wessels
BVBob de Vos
Bob de Vos
PMPim Moeskops
Pim Moeskops
MKMadeleine Kok
Madeleine Kok
In contrast-enhanced computed tomography, total body weight adapted contrast injection protocols have proven successful in achieving a homogeneous enhancement of vascular structures and liver parenchyma. However, because solid organs have greater perfusion than adipose tissue, the lean body weight (fat-free mass) rather than the total body weight is theorised to cause even more homogeneous enhancement. We included 102 consecutive patients who underwent a multiphase abdominal computed tomography between March 2016 and October 2019. Patients received contrast media (300 mgI/mL) according to bodyweight categories. Using regions of interest, we measured the Hounsfield unit (HU) increase in liver attenuation from unenhanced to contrast-enhanced computed tomography. Furthermore, subjective image quality was graded using a four-point Likert scale. An artificial intelligence algorithm automatically segmented and determined the body compositions and calculated the percentages of lean body weight. The hepatic enhancements were adjusted for iodine dose and iodine dose per total body weight, as well as percentage lean body weight. The associations between enhancement and total body weight, body mass index, and lean body weight were analysed using linear regression. Patients had a median age of 68 years (IQR: 58–74), a total body weight of 81 kg (IQR: 73–90), a body mass index of 26 kg/m2 (SD: ±4.2), and a lean body weight percentage of 50% (IQR: 36–55). Mean liver enhancements in the portal venous phase were 61 ± 12 HU (≤70 kg), 53 ± 10 HU (70–90 kg), and 53 ± 7 HU (≥90 kg). The majority (93%) of scans were rated as good or excellent. Regression analysis showed significant correlations between liver enhancement corrected for injected total iodine and total body weight (r = 0.53; p < 0.001) and between liver enhancement corrected for lean body weight and the percentage of lean body weight (r = 0.73; p < 0.001). Most benefits from personalising iodine injection using %LBW additive to total body weight would be achieved in patients under 90 kg. Liver enhancement is more strongly associated with the percentage of lean body weight than with the total body weight or body mass index. The observed variation in liver enhancement might be reduced by a personalised injection based on the artificial-intelligence-determined percentage of lean body weight.

25 November 2021 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
VCVéronique Valerie van Cooten
Véronique Valerie van Cooten
DJDaan J. de Jong
Daan J. de Jong
FWFrank J. Wessels
Frank J. Wessels
Pim de JongPim de Jong
Pim de Jong
MKMadeleine Kok
Madeleine Kok
This study’s aim was twofold. Firstly, to assess liver enhancement quantitatively and qualitatively in steatotic livers compared to non-steatotic livers on portal venous computed tomography (CT). Secondly, to determine the injection volume of contrast medium in patients with severe hepatic steatosis to improve the image quality of the portal venous phase. We retrospectively included patients with non-steatotic (n = 70), the control group, and steatotic livers (n = 35) who underwent multiphase computed tomography between March 2016 and September 2020. Liver enhancement was determined by the difference in attenuation in Hounsfield units (HU) between the pre-contrast and the portal venous phase, using region of interests during in three different segments. Liver steatosis was determined by a mean attenuation of ≤40 HU on unenhanced CT. Adequate enhancement was objectively defined as ≥50 ΔHU and subjectively using a three-point Likert scale. Enhancement of non-steatotic and steatotic livers were compared and associations between enhancement and patient- and scan characteristics were analysed. Enhancement was significantly higher among the control group (mean 51.9 ± standard deviation 11.5 HU) compared to the steatosis group (40.6 ± 8.4 HU p for difference < 0.001). Qualitative analysis indicated less adequate enhancement in the steatosis group: 65.7% of the control group was rated as good vs. 8.6% of the steatosis group. We observed a significant correlation between enhancement, and presence/absence of steatosis and grams of iodine per total body weight (TBW) (p < 0.001; adjusted R2 = 0.303). Deduced from this correlation, theoretical contrast dosing in grams of Iodine (g I) can be calculated: g I = 0.502 × TBW for non-steatotic livers and g I = 0.658 × TBW for steatotic livers. Objective and subjective enhancement during CT portal phase were significantly lower in steatotic livers compared to non-steatotic livers, which may have consequences for detectability and contrast dosing.

25 June 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
DJDaan J. de Jong
Daan J. de Jong
VCVéronique Valerie van Cooten
Véronique Valerie van Cooten
WVWouter Veldhuis
Wouter Veldhuis
Pim de JongPim de Jong
Pim de Jong
MKMadeleine Kok
Madeleine Kok
This study analyzes the homogeneity in liver attenuation of a body-weight-based protocol compared to a semi-fixed protocol. Patients undergoing abdominal multiphase computed tomography received 0.500 g of iodine (gI) per kilogram of body weight. Liver attenuation and enhancement were determined using regions of interest on scans in the pre-contrast and portal venous phases. The outcomes were analyzed for interpatient uniformity in weight groups. The subjective image quality was scored using a four-point Likert scale (excellent, good, moderate, and nondiagnostic). A total of 80 patients were included (56.3% male, 64 years, 78.0 kg) and were compared to 80 propensity-score-matched patients (62.5% male, 63 years, 81.7 kg). The liver attenuation values for different weight groups of the TBW-based protocol were not significantly different (p = 0.331): 109.1 ± 13.8 HU (≤70 kg), 104.6 ± 9.70 HU (70–90 kg), and 105.1 ± 11.6 HU (≥90 kg). For the semi-fixed protocol, there was a significant difference between the weight groups (p < 0.001): 121.1 ± 12.1 HU (≤70 kg), 108.9 ± 11.0 HU (70–90 kg), and 105.0 ± 9.8 HU (≥90 kg). For the TBW-based protocol, the enhancement was not significantly different between the weight groups (p = 0.064): 46.2 ± 15.1 HU (≤70 kg), 59.3 ± 6.8 HU (70–90 kg), and 52.1 ± 11.7 HU (≥90 kg). Additionally, for the semi-fixed protocol, the enhancement was not significantly different between the weight groups (p = 0.069): 59.4 ± 11.0 HU (≤70 kg), 53.0 ± 10.3 HU (70–90 kg), and 52.4 ± 7.5 HU (≥90 kg). The mean administered amount of iodine per kilogram was less for the TBW-based protocol compared to the semi-fixed protocol: 0.499 ± 0.012 and 0.528 ± 0.079, respectively (p = 0.002). Of the TBW-based protocol, 17.5% of the scans scored excellent enhancement quality, 76.3% good, and 6.3% moderate. Of the semi-fixed protocol, 70.0% scored excellent quality, 21.3% scored good, and 8.8% scored moderate. In conclusion, the TBW-based protocol increased the interpatient uniformity of liver attenuation but not the enhancement in the portal venous phase compared to the semi-fixed protocol, using an overall lower amount of contrast media and maintaining good subjective image quality.

17 August 2021 in Investigative Radiology
Verified
Journal Article
Closed access
SSSimone van der Star
Simone van der Star
DJDaan J. de Jong
Daan J. de Jong
RBRonald L.A.W. Bleys
Ronald L.A.W. Bleys
HKHugo J. Kuijf
Hugo J. Kuijf
ASArnold Schilham
Arnold Schilham
MKMadeleine Kok
Madeleine Kok
Objectives: The aim of this study was to investigate the interscanner and interscoring platform variability of calcium quantification in peripheral arteries of the lower extremities. Materials and Methods: Twenty human fresh-frozen legs were scanned using 3 different computed tomography (CT) scanners. The radiation dose (CTDIvol) was kept similar for all scanners. The calcium scores (Agatston and volume scores) were quantified using 4 semiautomatic scoring platforms. Comparative analysis of the calcium scores between scanners and scoring platforms was performed by using the Friedman test; post hoc analysis was performed by using the Wilcoxon signed rank test with Bonferroni correction. Results: Sixteen legs had calcifications and were used for data analysis. Agatston and volume scores ranged from 12.1 to 6580 Agatston units and 18.2 to 5579 mm3. Calcium scores differed significantly between Philips IQon and Philips Brilliance 64 (Agatston: 19.5% [P = 0.001]; volume: 14.5% [P = 0.001]) and Siemens Somatom Force (Agatston: 18.1% [P = 0.001]; volume: 17.5% [P = 0.001]). The difference between Brilliance 64 and Somatom Force was smaller (Agatston: 5.6% [P = 0.778]; volume: 7.7% [P = 0.003]). With respect to the interscoring platform variability, OsiriX produced significantly different Agatston scores compared with the other 3 scoring platforms (OsiriX vs IntelliSpace: 14.8% [P = 0.001] vs Syngo CaScore: 13.9% [P = 0.001] vs iX viewer: 13.2% [P < 0.001]). For the volume score, the differences between all scoring platforms were small ranging from 2.9% to 4.0%. Post hoc analysis showed a significant difference between OsiriX and IntelliSpace (3.8% [P = 0.001]). Conclusions: The use of different CT scanners resulted in notably different Agatston and volume scores, whereas the use of different scoring platforms resulted in limited variability especially for the volume score. In conclusion, the variability in calcium quantification was most evident between different CT scanners and for the Agatston score.

7 May 2026 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
DJDaan J. de Jong
Daan J. de Jong
PMPam C. G. Molenaar
Pam C. G. Molenaar
VVVera Verhoef
Vera Verhoef
LNLenka Novakova
Lenka Novakova
ECElisa Colato
Elisa Colato
TFTom A. N. Fuchs
Tom A. N. Fuchs
Background: In multiple sclerosis (MS), symbol digit modalities test (SDMT) scores are often influenced by practice effects. We evaluated the SDMT practice effect as a proxy of cognitive performance by relating it to disease severity and future performance. Methods: People with MS (pwMS) and healthy controls (HCs) were evaluated at baseline and five-year follow-up. Practice effects were modeled using two-part piecewise linear regression on daily smartphone SDMT (sSDMT) scores. Cognitive impairment (CI) and preservation (CP) were defined relative to HC baseline sSDMT z -scores (CI: z < −1.67, CP: z ≥ −1.67). Practice outcomes across HC/CP/CI were compared using ANCOVA and correlated to baseline variables. They were also assessed in relation to clinical outcomes and brain volumes in cross-sectional and baseline–follow-up models. Results: 85 pwMS (CP/CI: 66/19) and 20 HCs were analyzed. 73 pwMS completed follow-up (5.39 ± 0.38y). A practice plateau occurred in 80%/82%/100% of HC/CI/CP. Higher baseline sSDMT was related to higher plateau sSDMT ( ρ = 0.930, p < 0.001) and lower %-increase ( ρ = −0.266, p = 0.013). %-increase was higher in CI than CP (CI/CP = 22.0%/15.5 adj. p = 0.004), but the absolute ∆-increase and breakpoint were similar across groups. Associations of disability, cognition, and brain volumes with the plateau sSDMT were stronger when compared to the baseline sSDMT. No other associations were found cross-sectionally and in the baseline-follow-up models. Conclusions: Early-phase sSDMT practice effects were related to cognitive performance but were unique to disease status or associated with disease severity in pwMS. Plateau sSDMT showed stronger associations with disability and brain volumes than baseline performance. Interpretation of SDMT performance should therefore consider practice effects.

14 October 2026 in Multiple Sclerosis Journal
Verified
Journal Article
Open access
MWMark H. J. Wessels
Mark H. J. Wessels
DJDaan J. de Jong
Daan J. de Jong
MBMar Barrantes-Cepas
Mar Barrantes-Cepas
JJJulia R. Jelgerhuis
Julia R. Jelgerhuis
ZLZoë van Lierop
Zoë van Lierop
ESEva Strijbis
Eva Strijbis
Background: Long-term studies on multiple sclerosis progression often face dropout, possibly among those with more aggressive disease, biasing the cohort. Objectives: We assessed potential survivorship bias in a long-term observational multiple sclerosis cohort. Methods: Three hundred sixty-one patients with multiple sclerosis were followed for 10 years, with clinical assessments, blood biomarkers and magnetic resonance imaging at baseline, follow-up 1 and follow-up 2. Progression was defined as an Expanded Disability Status Scale increase. Dropout was analysed and predicted; estimated Expanded Disability Status Scale was calculated for dropouts to assess bias. Brain volumes were normalized. Results: One hundred and sixty-two patients with multiple sclerosis completed all follow-ups; 81 showed progression. Dropout rates were 97/361 at follow-up 1 and 102/264 at follow-up 2. Dropouts had worse Expanded Disability Status Scale, Nine-Hole Peg test, Timed 25-Foot Walk, lower brain volume and higher lesion volume before dropping out. Blood biomarkers did not differ. Main dropout predictors were higher baseline Expanded Disability Status Scale, lesion volume, worse Nine-Hole Peg test and shorter disease duration. Median estimated Expanded Disability Status Scale at follow-up 2 for dropouts was 5.5 versus 3.5 for non-dropouts. Discussion: Fewer than half completed the study. High lesion load and worse clinical status predicted dropout. This may cause underestimation of progression and reduced statistical power. Similar bias may affect other long-term studies in chronic diseases.